PRS17 THE BUDGET IMPACT OF DUORESP® SPIROMAX® (BUDESONIDE + FORMOTEROL FUMARATE DIHYDRATE) COMPARED WITH COMMONLY PRESCRIBED DRY POWDER INHALERS FOR THE MANAGEMENT OF ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN THE UNITED KINGDOM: IMPACT OF INHALATION TECHNIQUE  by Lewis, A. et al.
A172  VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 1 – A 3 0 7  
Spiromax® inhaler was also investigated. Methods: The eligible adult patient 
population was based on current confirmed UK asthma and COPD diagnosis rates, 
with the proportion receiving FDCs based on market research data.  Costs of FDCs 
and scheduled and unscheduled healthcare events were taken from publicly avail-
able UK sources.  Frequency of poor inhalation technique with the market-leading 
DPIs, and the associated increased risk of unscheduled healthcare events, were 
taken from a large (n=1,664) cross-sectional, Italian observational study, with the 
estimated reduction in the proportion of patients with poor inhalation technique 
with DuoResp® Spiromax® based on a conservative assumption. Results: The 
model estimated that 400,926 adult patients use Symbicort® Turbohaler® and 
357,008 Seretide® Accuhaler® annually and were therefore eligible for treatment 
with DuoResp® Spiromax®, with 174,403 and 123,168 of these exhibiting poor 
inhalation technique, respectively.  Assuming a hypothetical uptake of DuoResp® 
Spiromax® reaching 13% in year 4 and 5, and its current UK price, the model 
predicted drug cost savings totalling £65.57 million over five years.  Furthermore, 
64,845 unscheduled healthcare events could be avoided due to the predicted 
improvement in inhalation technique with DuoResp® Spiromax® compared with 
these DPIs, resulting in further savings of £4.78 million. ConClusions: DuoResp® 
Spiromax® is likely to offer budgetary savings compared with market-leading 
DPIs, with further cost savings potentially resulting from improved inhalation 
technique.
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objeCtives: To estimate and compare the use and frequency of medical resources 
needed in the treatment of exacerbation episodes in patients with COPD at out-
patient and inpatient care levels from a public Mexican institutional perspec-
tive, in this case insured patients from the “Instituto Mexicano del Seguro Social” 
(IMSS). Methods: From January to December 2013, a retrospective study was 
performed to estimate the direct medical costs of COPD exacerbations. The level 
of acuteness and treatment patterns used for the study where the same as those 
defined by the institution (IMSS guideline). Patient records were retrieved from 
the open institutional electronic databases for a 11822 COPD patients cohort. 
Exacerbation episodes were classified according to the guideline. Inpatient and 
outpatient care was the criteria for assessing the use and frequency of medical 
resources, including relevant outcomes as hospitalization, physician visits, inten-
sive care unit, surgery, medication use, clinical studies among others. Unitary costs 
were obtained from public tabulators (2014 IMSS). Mean frequency values were 
weighted with its corresponding costs. Results: In 2013, 16122 episodes of exac-
erbation were reported by the studied subjects. Patients over 45 years represented 
97% of all cases; being those over 65 years the most frequent (81%). A mean average 
of 5.6 days of inpatient care was founded at the study horizon. Yearly weighted 
cost of treatment for outpatient and inpatient care was US$8,630 and US$51,259 
respectively. A unitary item costs analysis from the inpatient versus the outpa-
tient treatment groups founded a significant increase in medication use (+83%), 
specialty visits (+100%), surgery (+100%) among other items. ConClusions: In 
the treatment of exacerbation episodes in patients with COPD, the aggregated 
cost per year of inpatient versus outpatient care was estimated to be 83% higher. 
Reducing the risk of exacerbation episodes with the right treatment choice would 
be relevant for Mexican institutions.
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objeCtives: Allergic rhinitis (AR) affects 20% of the population, and 40% of these 
patients report a diagnosis of asthma. Previous work has shown that treatment of 
AR improves asthma control. The objective was to examine healthcare costs related 
to AR and asthma for patients either treated with MP29-02*, a novel intranasal for-
mulation of azelastine hydrochloride and fluticasone propionate in an advanced 
delivery system, or combination therapy with single ingredient intranasal antihis-
tamine (INA) and intranasal corticosteroid (INS) sprays. Methods: A retrospective 
analysis of medical and pharmacy claims of a commercially-insured U.S. popula-
tion was performed to evaluate differences in costs between two treatment groups 
(MP29-02* and INA/INS combination therapy). Medical and pharmacy claims occurring 
between 9/1/2011-3/31/2014 were used. Inclusion criteria included a diagnosis of rhi-
nitis (defined by ICD-9 472.0, 477.xx), at least 1 claim for a prescription intranasal spray 
(designated as the index date) during the identification period (9/1/2012—12/31/2013), 
12 months pre-index and 6-months post-index continuous enrollment, and no pre-
index claims for an intranasal spray. Patients diagnosed with asthma (493.xx) during 
the observation period were flagged. Inverse propensity score weighting adjustment 
was used to control for demographic, comorbidity, geographical and seasonal attrib-
utes. Adjusted mean AR-related and asthma-related costs for 6-months post-index 
were compared. Results: Total medical and pharmacy costs for the MP29-02* cohort 
(n= 810) are $2,782, statistically significant lower than for INA/INS cohort (n= 726) with 
$3,493 (P= .0074). For the sub-cohort with asthma, the MP29-02* cohort (n= 109) had 
lower asthma-related pharmacy costs ($247 vs. $796, P= .0193) and lower total asthma-
related costs ($565 vs. $1068, P= .0311) compared to the INA/INS asthmatic sub-cohort 
(n= 113). ConClusions: For individuals with asthma and rhinitis, MP29-02* is asso-
ciated with lower asthma-related costs compared to sequential INA/INS therapy in 
particular for pharmacy costs highlighting the economic impacts of formulation and 
delivery system in intranasal AR therapy. *Dymista
stay served to contribute to a 0.19% probability increase of 30-day readmissions 
(p< 0.001). ConClusions: Several comorbidities and a previous record of hospi-
talizations served as risk factors for 30-day readmissions. Patients with these risk 
factors are vulnerable and merit special attention.
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objeCtives: The societal economic burden of asthma was $56 billion (direct and 
indirect costs) in 2007. Inpatient costs represented 28%-43% of the total direct costs 
(excluding prescription costs). The objective of this study is to estimate the deter-
minants of 30-day hospital readmissions among patients with asthma. Methods: 
A cross-sectional analysis was conducted for patients with asthma (ICD 9 code 
493) among all age groups utilizing the 2012 Truven MarketScan dataset. Patients 
discharged to home or other facilities were included (un-weighted n= 16,390). 
A multivariable logit model was employed where the outcome variable was a 
dichotomous 30-day readmission (any caused readmission). The covariates 
included demographic characteristics, length of stay at index hospitalization, 
past healthcare utilizations, and comorbidities. Results: Among patients 
with asthma, the readmission rate within 30 days after the index hospitaliza-
tion discharge was 4.8%. Older groups were more likely to be readmitted than 
younger group (17-34 aged): Odds ratio (OR)= 1.59 (35-44 aged, p= 0.023), 1.61 (45-
54 aged, p= 0.012) and 1.71 (55-64 aged, p= 0.007). Patients with HMO, PPO and 
Comprehensive insurances were 72% more (OR= 1.72, p< 0.001), 31% less (OR= 0.69, 
p= 0.031) and 68% less (OR= 0.32, p< 0.001) likely to be readmitted than those with 
PPO, respectively. Patients discharged to other facilities were 388% (OR= 4.88, 
p< 0.001) more likely to be readmitted than those discharged to home. Patients 
with connective tissue disease were 63% (OR= 1.63, p= 0.007) more likely to be 
readmitted within 30 days than those without. In addition, an increase of hospi-
talization in the prior year contributed to a 1.36% probability increase of 30-day 
readmissions (p< 0.001). ConClusions: Patient groups vulnerable for 30-day 
readmissions after hospitalization were identified among patients with asthma. 
A comorbidity disease and a previous record of healthcare utilization were risk 
factors for 30-day readmission.
ReSPIRatORy-Related dISORdeRS – cost Studies
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objeCtives: To estimate annual drug wastage (drug that is discarded without being 
administered to a patient) and associated costs incurred by a typical hospital due to 
the use of multi-unit-dose packaged COPD treatment devices in patients admitted 
for acute chronic obstructive pulmonary disease (COPD) exacerbation. Methods: 
An economic model was built to evaluate the annual number of wasted doses and 
related costs associated with adult patients admitted to the hospital for an acute 
COPD exacerbation. Model inputs were based on a retrospective study of adults with 
COPD admitted to a university-affiliated hospital between January 2011 and June 2012 
(Sakaan, Am J Respir Crit Care Med. 2014). Wasted doses for the following comparators 
were assessed: albuterol, arformoterol, fluticasone, formoterol, ipratropium, tiotro-
pium, budesonide/formoterol, and fluticasone/salmeterol (all non-nebulized formu-
lations except arformoterol). Because arformoterol is available in a single-unit-dose 
package, no wastage was assumed. Pharmacy costs of wasted doses were calculated 
from number of doses wasted and publicly available wholesale acquisition cost per 
dose (Red Book™, 2014). Results: Based on a hospital with 500 COPD admissions 
per year, the estimated annual number of wasted doses was 18,045 (87%) at a cost of 
$69,103. Budesonide/formoterol, tiotropium, and fluticasone/salmeterol were most 
costly, representing an annual cost of $28,292, $17,686, and $17,366 in drug wastage, 
respectively. Arformoterol ($0), formoterol ($518), and fluticasone ($550) had the low-
est annual drug wastage costs. The highest drug wastage costs per patient were with 
fluticasone ($195) and budesonide/formoterol ($161), while the lowest drug wastage 
costs per patient were with arformoterol ($0) and albuterol ($17). ConClusions: For 
patients admitted to the hospital with a COPD exacerbation, the use of multi-unit-
dose packaged devices may result in significant costs due to drug wastage that could 
be avoided with use of single-unit-dose packaged devices.
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objeCtives: DuoResp® Spiromax® (budesonide + formoterol fumarate dihy-
drate) is a fixed-dose combination (FDC) of inhaled corticosteroid (ICS) + long-
acting beta agonist (LABA) in a novel dry powder inhaler (DPI).  An economic 
model was developed to assess the budget impact of switching adult patients 
with persistent asthma and chronic obstructive pulmonary disease (COPD) from 
market-leading DPIs in the United Kingdom (UK)  - Symbicort® Turbohaler® and 
Seretide® Accuhaler®  - to DuoResp® Spiromax®.  The potential cost benefit 
of improved inhalation technique due to the innovative characteristics of the 
